IN RE: GUILD MORTGAGE COMPANY
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Before Moore, Reyna, and Chen. Appeal from the Trademark Trial and Appeal Board.
Summary: The TTAB must consider Applicant’s evidence and argument as to an absence of actual confusion during the period of concurrent use of allegedly confusing marks.
Guild Mortgage Co. (“Guild”) applied to the PTO to register the mark “GUILD MORTGAGE COMPANY.” The Examiner refused the registration, citing a likelihood of confusion with the registered mark “GUILD INVESTMENT MANAGEMENT.” Guild responded by arguing that “it and Registrant have coexisted in business [in Southern California] for over 40 years without any evidence of actual confusion” (DuPont factor 8) and submitted a declaration of its President and CEO in support of this argument. The Examiner rejected this argument in a final office action. The TTAB affirmed the Examiner’s refusal to register Guild’s mark. In its opinion, the Board did not mention DuPont factor 8 and failed to address Guild’s argument and evidence directed to this factor.
The Federal Circuit vacated and remanded the decision. The Federal Circuit clarified that its previous holding in Majestic Distilling with respect to “the seventh DuPont factor” that “uncorroborated statements of no known instances of actual confusion are of little evidentiary value” does not extend to the eighth DuPont factor. The Federal Circuit noted that Guild “presented evidence of concurrent use of the two marks for a particularly long period of time … in which the two businesses operated in the same geographic market … without any evidence of actual confusion.” The Federal Circuit held that the Board, in determining the likelihood of confusion, must consider Guild’s “absence of actual confusion” evidence and argument and balance the evidence against other DuPont factors.
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…